FORA Capital’s Revance Therapeutics, Inc. RVNC Stock Holding History

FORA Capital’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-60,868	Closed	-$185K	–	669
2024 Q4	$185K	Buy	60,868 +50,501	+487%	+$220K	0.02%	358
2024 Q3	$53.8K	Buy	+10,367	New	+$51.5K	0.01%	421
2021 Q3	–	Sell	-2,829	Closed	-$84K	–	920
2021 Q2	$84K	Buy	2,829 +2,145	+314%	+$61.9K	0.02%	629
2021 Q1	$19K	Sell	684 -15	-2%	-$415	0.01%	695
2020 Q4	$20K	Sell	699 -4,747	-87%	-$123K	﹤0.01%	873
2020 Q3	$137K	Buy	5,446 +1,468	+37%	+$38.5K	0.09%	238
2020 Q2	$97K	Buy	3,978 +353	+10%	+$6.97K	0.03%	504
2020 Q1	$54K	Buy	+3,625	New	+$75K	0.01%	750

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

FORA Capital's RVNC Position: Q1 2025 in Review

FORA Capital sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 60,868 shares — an estimated $185K sold.

FORA Capital first reported a position in RVNC in Q1 2020 and held it in 8 quarters. The position peaked at $185K in Q4 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

FORA Capital reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
FORA Capital sold 60,868 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $185K.
FORA Capital first reported a position in Revance Therapeutics, Inc. in Q1 2020 and held it in 8 quarters.
FORA Capital's Revance Therapeutics, Inc. position peaked at $185K in Q4 2024.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on FORA Capital's 13F filing for Q1 2025, filed 14 May 2025.